HIGH

Harbin Jixianglong Biotech Semaglutide Rx Compounding Recall 2026 — 6 Packaging Sizes

Harbin Jixianglong Biotech Co. recalled Semaglutide for Rx compounding use nationwide in the United States. The recall cites CGMP deviations and failure to complete endotoxin validation before distribution. Healthcare providers and patients should stop using the product immediately and contact the company or a healthcare provider for guidance via email.

Quick Facts at a Glance

Recall Date
February 13, 2026
Hazard Level
HIGH
Brand
Harbin Jixianglong Biotech Co.
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Harbin Jixianglong Biotech Co., Ltd. or your healthcare provider for guidance. Notification method: E-Mail

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Semaglutide for Rx compounding is used to prepare customized pharmaceutical products for patients under medical supervision.

Why This Is Dangerous

CGMP deviations and lack of validated endotoxin testing raise risk of contaminated injectable product and possible infection.

Industry Context

This recall is not described as part of a broader industry pattern.

Real-World Impact

Potential endotoxin exposure could lead to severe infection in patients requiring medical treatment.

Practical Guidance

How to identify if yours is affected

  1. Verify NDCs for the product: 84385-106-01, -02, -06, -03, -04, -05.
  2. Check Lot: CP-030-20250911.
  3. Confirm manufacturing date: Sep 25, 2025.
  4. Check retest date: Sep 24, 2027.

Where to find product info

FDA enforcement recall page for D-0380-2026; recall notice details.

What timeline to expect

Not specified by the recall notice; use FDA guidance and company contact for updates.

If the manufacturer is unresponsive

  • Escalate to FDA recall contact channels.
  • File consumer complaint if no resolution within a reasonable time.
  • Keep copies of all correspondence and recall notices.

How to prevent similar issues

  • Require CGMP-compliant suppliers for compounding drugs.
  • Verify endotoxin testing and batch validation before distribution.
  • Keep batch numbers and NDCs for future recalls.

Documentation advice

Save recall notice, batch numbers, manufacturer contact, and medical records if exposure occurs.

Product Details

Product: Semaglutide for Rx compounding use only. Packaging sizes and NDCs: 1 g (84385-106-01); 5 g (84385-106-02); 10 g (84385-106-06); 25 g (84385-106-03); 50 g (84385-106-04); 100 g (84385-106-05). Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China. Distribution: Nationwide in the United States. Recall Date: 2026-02-13. Report Date: 2026-03-11. Classification: Class II. Quantity: N/A.

Key Facts

  • 6 packaging sizes recalled: 1 g, 5 g, 10 g, 25 g, 50 g, 100 g
  • NDCs: 84385-106-01; 84385-106-02; 84385-106-06; 84385-106-03; 84385-106-04; 84385-106-05
  • Batch CP-030-20250911
  • Mfg Date: Sep 25, 2025
  • Retest Date: Sep 24, 2027
  • Recall date: 2026-02-13; Report date: 2026-03-11; Status: Active

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
7/ 10
Affected Groups
GENERAL
Injury Types
POISONINGOTHER

Product Details

Model Numbers
Batch CP-030-20250911
Mfg Date: Sep 25, 2025
Retest Date: Sep 24, 2027
2025
2027
Affected States
ALL
Report Date
March 11, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more